ProMetic To Report Results Of PBI-1402 Data At Upcoming Annual Meeting Of American Society Of Nephrology

Main Category: Urology / Nephrology
Article Date: 26 Oct 2009 - 8:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") announced that it has been selected by the American Society of Nephrology for multiple presentations regarding PBI-1402 at its 42nd Annual Meeting & Scientific Exposition, being held from October 27 to November 1, 2009, in San Diego, California.

ProMetic's orally active lead compound for the treatment of anemia, PBI-1402, is in clinical development for the treatment of anemia induced by chemotherapy ("CIA") and/or related to cancer ("CRA"). A Phase Ib/II clinical trial demonstrated significant increases in hemoglobin and red blood cells as well as a reduction of the need for blood transfusion in patients with CIA.

PBI-1402's therapeutic activity has been further tested in well established animal models designed to simulate different renal diseases in humans. The presentations will be highlighting some of these significant preclinical results.

Dr. Lyne Gagnon, ProMetic's Director of Research and Development, Biology, and other investigators, will be presenting data during three poster sessions at the following times:

- Thursday, October 29, 2009 from 10:00 - 12:00 (PST) - Poster Session TH-PO102 - Oral treatment with PBI-1402 improves glomerular filtration rate by reducing tubulo-interstitial fibrosis and sclerosis in 5/6 nephrectomized (NX) rats;

- Saturday, October 31, 2009 from 10:00 - 12:00 (PST) - Poster Session SA-PO2200 - Oral treatment of PBI-1402 prevents doxorubicin-induced nephrotoxicity in mice;

- Saturday, October 31, 2009 from 10:00 - 12:00 (PST) - Poster Session SA-PO2424 - Oral treatment with PBI-1402 increases hemoglobin, hematocrit and red blood cell formation in 5/6 nephrectomized (NX) rats, a model mimicking human end-stage renal disease (ESRD).

Source
ProMetic Life Sciences Inc.

Article adapted by Medical News Today from original press release.
Visit our urology / nephrology section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
ProMetic Life Sciences Inc. "ProMetic To Report Results Of PBI-1402 Data At Upcoming Annual Meeting Of American Society Of Nephrology." Medical News Today. MediLexicon, Intl., 26 Oct. 2009. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/168716.php>

APA
ProMetic Life Sciences Inc. (2009, October 26). "ProMetic To Report Results Of PBI-1402 Data At Upcoming Annual Meeting Of American Society Of Nephrology." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/168716.php.

Please note: If no author information is provided, the source is cited instead.


Urology / Nephrology

Most Popular Articles



Follow Our Urology News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Urology / Nephrology Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »